News
Roche, Rona Therapeutics Partner to Develop RNAi Therapy for Obesity
Rona Therapeutics enters into a $1.16 billion global licensing agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Rona Therapeutics enters into a $1.16 billion global licensing agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
